Replies to post #72720 on Biotech Values

[genisi]

ITMN - on the differences between the CAPACITY 1&2 out comes

...a sicker patient population group in Capacity 1 (specifically Oxygen use 2x that of Capacity 2 and baseline 6MWT about 10% lower than Capacity 2)

Makes a lot of sense to me that if pirfenidone works better in early stage of IPF i.e. mild patients, and Capacity 1 has more severely ill population, this could explain the big difference between the trials.